IVI and Austria
Member State Relations
On 13 June 2024, Austria deposited an instrument of accession to the IVI Establishment Agreement with the United Nations, following ratification by Parliament.
State Funder
The Austrian government annually contributes 800,000€ in core funding to IVI, provided through the Federal Ministry of Education, Science and Research (BMBWF) and the Federal Ministry of Social Affairs, Health, Care and Consumer Protection (BMSGPK). This funding is used, in part, to integrate the capacities of Austrian research institutes and biotech firms in vaccine R&D into global health initiatives to combat the spread of infectious diseases and future pandemics.
The City of Vienna and the Federal Ministry of European and International Affairs (BMEIA) provide annual rent reimbursement to the IVI-Austria Country Office.
Host Country Agreement
In 2023, the Austrian government and IVI entered into a Host Country Agreement to facilitate the establishment of the IVI-Austria Country Office.
For more information on the IVI-Austria Country Office, click here.
Austrian Leadership at IVI
Dr. Christian W. Mandl, Vaccines and Viral Vectors, (2024-Present), Chair of Scientific Committee, Member-at-Large
Dr. Christian W. Mandl, Vaccines and Viral Vectors (2018-2014) SAG Chairperson
Previous Collaboration
Influenza Vaccine Development
In 2010, IVI initiated studies with Avir Green Hills Biotechnology AG of Austria involving sublingual administration of NS-1 deleted influenza virus constructs in animals and evaluation of the immune response and protection against experimental challenge with different virulent influenza strains.
The Delta NS1 Vaccine Platform is now a “versatile and robust technology platform for broadly protective, self-adjuvanting vaccines administered by nasal spray. Delta NS1 is a replication-deficient vaccine vector based on a genetically modified, safely attenuated influenza virus strain.”